



PSORIASIS AND PSORIATIC ARTHRITIS SPECIALTY CARE PROGRAM

Phone: **856-963-4742** • Fax: **856-541-8580**



1 PATIENT INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Alt. Phone: _____
 Email: _____
 DOB: _____ Gender: M F Caregiver: _____
 Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 NPI: _____ DEA: _____
 Tax I.D.: _____
 Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____
 ICD-10: _____ Other: _____
 TB Test: Positive Negative Date: _____
 LFT: ALT: _____ AST: _____ Date: _____
 Assessment: Moderate Mod to Severe Severe
 _____% BSA affected
 Scalp Face Chest Arms Hands Nails
 Back Groin Buttocks Legs Other: _____

Patient also taking Methotrexate? Yes No
 Serious or active infection present? Yes No
 Hep B ruled out or treatment started? Yes No
 Does patient have latex allergy? Yes No
 Does patient have joint involvement? Yes No
 If yes, please indicate affected joint(s): _____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Prior Failed Treatments:

Topicals _____
 Methotrexate _____
 Oral Meds _____
 Biologics _____
 UVA UVB _____
 Others _____

4 INJECTION TRAINING: To be Administered by a Healthcare Provider Pharmacist to Provide Training Patient Trained in MD Office Manufacturer Nurse Support

5 PICK UP OR DELIVERY: Delivery to Patient's Home Delivery to Physician's Office Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> CIMZIA®	<input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Powder Vial	Plaque Psoriasis: <input type="checkbox"/> Inject 400mg SC every other week <input type="checkbox"/> Induction Dose: (Weight ≤90kg) Inject 400mg SC initially and at weeks 2 and 4 <input type="checkbox"/> Maintenance Dose: (Weight ≤90kg) Inject 200mg SC every other week Psoriatic Arthritis: <input type="checkbox"/> Initial: Inject 400 mg SC initially and at weeks 2 and 4 <input type="checkbox"/> Maintenance: Inject 200mg SC every other week <input type="checkbox"/> Maintenance: Inject 400mg SC every 4 weeks		
<input type="checkbox"/> ENBREL®	<input type="checkbox"/> 50mg/ml Sureclick Autoinjector	<input type="checkbox"/> Induction Dose: Inject 50mg SC twice a week (3-4 days apart) for 3 months, then start maintenance dosing	8	2
	<input type="checkbox"/> 50mg/ml Enbrel Mini™ Prefilled Cartridge For Enbrel Mini™ only: AutoTouch™ Autoinjector	<input type="checkbox"/> Maintenance: Inject 50mg SC once a week Pediatric Patients: To achieve pediatric doses other than 50mg or 25mg, use reconstituted Enbrel lyophilized powder	4	
	<input type="checkbox"/> 50mg/ml Prefilled Syringe <input type="checkbox"/> 25mg/0.5ml Prefilled Syringe <input type="checkbox"/> 25mg Lyophilized Powder Multiple Dose Vial <input type="checkbox"/> Other: _____	<input type="checkbox"/> > 138lbs or more: Inject 50mg weekly <input type="checkbox"/> < 138lbs: Inject 0.8mg/kg weekly <input type="checkbox"/> Other: _____	4	
<input type="checkbox"/> HUMIRA®	<input type="checkbox"/> Psoriasis 80mg/0.8ml and 40mg/0.4ml Starter Package <input type="checkbox"/> Psoriasis 40mg/0.4ml Starter Package	<input type="checkbox"/> Induction Dose: Inject 80mg SC on day 1, then 40mg SC on day 8, then 40mg SC every other week <input type="checkbox"/> Maintenance: Inject 40mg SC every other week <input type="checkbox"/> Other: _____	3	0
	<input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe		4	0
	<input type="checkbox"/> Hidradenitis Suppurativa 80mg/0.8ml Starter Package <input type="checkbox"/> Hidradenitis Suppurativa 40mg/0.4ml Starter Package	<input type="checkbox"/> Induction Dose: <input type="checkbox"/> Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 <input type="checkbox"/> Inject one 80mg pen SC on day 1, one 80mg pen on day 2, then one 80mg pen on day 15	3	0
	<input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe	<input type="checkbox"/> Maintenance: Inject 40mg SC on day 29 and every week thereafter <input type="checkbox"/> Patient has signed HUMIRA Complete form	6	0
	<i>All strengths and dosages listed are Humira® Citrate Free</i>			
<input type="checkbox"/> ORENCIA®	<input type="checkbox"/> 125mg/ml ClickJect™ Autoinjector <input type="checkbox"/> 125mg/ml Prefilled Syringe	<input type="checkbox"/> Inject 125mg SC once a week	4	
<input type="checkbox"/> OTEZLA®	<input type="checkbox"/> Starter Pack (Titration)	<input type="checkbox"/> Starter Pack: Take one tablet in the morning on day 1, then take one tablet in the morning and one tablet in the evening as directed on the starter pack	1	0
	<input type="checkbox"/> 30mg Tablets	<input type="checkbox"/> Maintenance: Take one 30mg tablet by mouth twice daily	60	
<input type="checkbox"/>				

Rasuvo®, Simponi®, Skyrizi™, Stelara®, Tremfya™, Xeljanz® and Xeljanz® XR are listed alphabetically on respective enrollment forms.

PRESCRIBER SIGNATURE:

I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted

Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.



PSORIASIS AND PSORIATIC ARTHRITIS SPECIALTY CARE PROGRAM

Phone: **856-963-4742** • Fax: **856-541-8580**



1 PATIENT INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Alt. Phone: _____
 Email: _____
 DOB: _____ Gender: M F Caregiver: _____
 Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 NPI: _____ DEA: _____
 Tax I.D.: _____
 Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____
 ICD-10: _____ Other: _____
 TB Test: Positive Negative Date: _____
 LFT: ALT: _____ AST: _____ Date: _____
 Assessment: Moderate Mod to Severe Severe
 _____% BSA affected
 Scalp Face Chest Arms Hands Nails
 Back Groin Buttocks Legs Other: _____

Patient also taking Methotrexate? Yes No
 Serious or active infection present? Yes No
 Hep B ruled out or treatment started? Yes No
 Does patient have latex allergy? Yes No
 Does patient have joint involvement? Yes No
 If yes, please indicate affected joint(s): _____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Prior Failed Treatments:

Topicals _____
 Methotrexate _____
 Oral Meds _____
 Biologics _____
 UVA UVB _____
 Others _____

4 INJECTION TRAINING: To be Administered by a Healthcare Provider Pharmacist to Provide Training Patient Trained in MD Office Manufacturer Nurse Support

5 PICK UP OR DELIVERY: Delivery to Patient's Home Delivery to Physician's Office Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> RASUVO®	Single-dose auto-injector prefilled syringe: <input type="checkbox"/> 7.5mg <input type="checkbox"/> 10mg <input type="checkbox"/> 12.5mg <input type="checkbox"/> 15mg <input type="checkbox"/> 17.5mg <input type="checkbox"/> 20mg <input type="checkbox"/> 22.5mg <input type="checkbox"/> 25mg <input type="checkbox"/> 27.5 mg <input type="checkbox"/> 30mg	<input type="checkbox"/> Inject _____ mg SC once weekly *An initial test dose of 2.5 to 5 mg is recommended in patients with risk factors for hematologic toxicity or renal impairment*		
<input type="checkbox"/> SIMPONI® (for PsA)	<input type="checkbox"/> 50mg/0.5ml Smartject Injector <input type="checkbox"/> 50mg/0.5ml Prefilled Syringe	<input type="checkbox"/> Inject 50mg SC once a month	1	
<input type="checkbox"/> SKYRIZI™	<input type="checkbox"/> 75mg/0.83ml Prefilled Syringe	<input type="checkbox"/> Induction Dose: Inject 150mg (two 75mg injections) SC at weeks 0 and 4	4	0
		<input type="checkbox"/> Maintenance: Inject 150mg (two 75mg injections) SC every 12 weeks thereafter	2	
<input type="checkbox"/> STELARA®	<input type="checkbox"/> 45 mg/0.5 mL Single-Dose Prefilled Syringe <input type="checkbox"/> 45 mg/0.5 mL Solution in a Single-Dose Vial	Plaque Psoriasis: <input type="checkbox"/> Adult dosing (≤100 kg): Inject 45 mg SC initially and at 4 weeks, then every 12 weeks thereafter <input type="checkbox"/> Adult Dosing (>100 kg): Inject 90 mg SC initially and at 4 weeks, then every 12 weeks thereafter		
		Psoriatic Arthritis: <input type="checkbox"/> Inject 45 mg SC initiation and at 4 weeks, then every 12 weeks thereafter		
<input type="checkbox"/> TREMFYA™	<input type="checkbox"/> 100mg/ml Prefilled Syringe <input type="checkbox"/> 100mg/ml One- Press Patient Controlled Injector	<input type="checkbox"/> Induction Dose: Inject 100mg/ml SC at weeks 0 and 4	2	0
		<input type="checkbox"/> Maintenance: Inject 100mg/ml SC every 8 weeks thereafter	1	
<input type="checkbox"/> XELJANZ®	<input type="checkbox"/> 5mg Tablet	<input type="checkbox"/> Take one tablet by mouth twice daily in combination with a nonbiologic DMARD	60	
<input type="checkbox"/> XELJANZ® XR	<input type="checkbox"/> 11mg Tablet	<input type="checkbox"/> Take one tablet by mouth once daily in combination with a nonbiologic DMARD	30	
<input type="checkbox"/> _____				

Cimzia®, Enbrel®, Humira®, Orencia™ and Otezla® are listed alphabetically on respective enrollment forms.

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted

Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

v9.1_020221

©2020 KloudScript, Inc. - All rights reserved.